Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.

<h4>Background</h4>Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatic cirrhosis and hepatocellular carcinoma, and HCV genotype 1 is the most prevalent genotype and is resistant to current standard therapy. We performed this meta-analysis to evaluate the eff...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yuan Kong, Xiaoping Wang, Yushu Shang, Paul M Schroder, Wenhua Liang, Xiaoting Ling, Zhiyong Guo, Xiaoshun He
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9bb02f5ccd264deb9697c71e82c55b96
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9bb02f5ccd264deb9697c71e82c55b96
record_format	dspace
spelling	oai:doaj.org-article:9bb02f5ccd264deb9697c71e82c55b962021-11-18T08:04:18ZEfficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.1932-620310.1371/journal.pone.0052158https://doaj.org/article/9bb02f5ccd264deb9697c71e82c55b962012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23284915/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatic cirrhosis and hepatocellular carcinoma, and HCV genotype 1 is the most prevalent genotype and is resistant to current standard therapy. We performed this meta-analysis to evaluate the efficacy and safety of telaprevir-based therapy for chronic HCV genotype 1 infection.<h4>Methods</h4>We included randomized controlled trials with no year or language restriction. All data were analyzed using a random-effects model by Review Manager v5.0. The primary outcome was the proportion of patients achieving sustained virologic response (SVR), and the secondary outcomes were HCV relapse rate, incidence of severe adverse events (SAEs), and discontinuation due to adverse events.<h4>Results</h4>The proportion of achieving SVR was significantly higher in the telaprevir group (odds ratio [OR] =3.40 [1.92, 6.00], P<0.0001; I(2) =87%) regardless of a patients' previous treatment status. It was also significantly higher in the 24-week and 48-week treatment groups (OR=4.52 [2.08, 9.81], P<0.001; I(2) =85%, and OR=4.05 [1.56, 10.56], P=0.004; I(2) =92%, respectively), while it was comparable in the 12-week treatment group (OR=1.32 [0.63, 2.75], P=0.46; I(2) =35%). In addition, the HCV relapse rate was significantly reduced in the telaprevir group (OR=0.28 [0.16, 0.49], P<0.001; I(2) =76%). However, the incidence of SAE (OR=1.56 [1.15, 2.10], P=0.004; I(2) =0%) and study discontinuation due to adverse events (OR=2.24 [1.43, 3.50], P<0.001; I(2) =37%) were significantly higher in the telaprevir group.<h4>Conclusion</h4>Despite its higher incidence of SAEs and discontinuation due to adverse events, telaprevir-based therapy can increase the proportion of achieving SVR in both previously treated and untreated chronic HCV-1 infected patients.Yuan KongXiaoping WangYushu ShangPaul M SchroderWenhua LiangXiaoting LingZhiyong GuoXiaoshun HePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 12, p e52158 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yuan Kong Xiaoping Wang Yushu Shang Paul M Schroder Wenhua Liang Xiaoting Ling Zhiyong Guo Xiaoshun He Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
description	<h4>Background</h4>Chronic hepatitis C virus (HCV) infection is one of the leading causes of hepatic cirrhosis and hepatocellular carcinoma, and HCV genotype 1 is the most prevalent genotype and is resistant to current standard therapy. We performed this meta-analysis to evaluate the efficacy and safety of telaprevir-based therapy for chronic HCV genotype 1 infection.<h4>Methods</h4>We included randomized controlled trials with no year or language restriction. All data were analyzed using a random-effects model by Review Manager v5.0. The primary outcome was the proportion of patients achieving sustained virologic response (SVR), and the secondary outcomes were HCV relapse rate, incidence of severe adverse events (SAEs), and discontinuation due to adverse events.<h4>Results</h4>The proportion of achieving SVR was significantly higher in the telaprevir group (odds ratio [OR] =3.40 [1.92, 6.00], P<0.0001; I(2) =87%) regardless of a patients' previous treatment status. It was also significantly higher in the 24-week and 48-week treatment groups (OR=4.52 [2.08, 9.81], P<0.001; I(2) =85%, and OR=4.05 [1.56, 10.56], P=0.004; I(2) =92%, respectively), while it was comparable in the 12-week treatment group (OR=1.32 [0.63, 2.75], P=0.46; I(2) =35%). In addition, the HCV relapse rate was significantly reduced in the telaprevir group (OR=0.28 [0.16, 0.49], P<0.001; I(2) =76%). However, the incidence of SAE (OR=1.56 [1.15, 2.10], P=0.004; I(2) =0%) and study discontinuation due to adverse events (OR=2.24 [1.43, 3.50], P<0.001; I(2) =37%) were significantly higher in the telaprevir group.<h4>Conclusion</h4>Despite its higher incidence of SAEs and discontinuation due to adverse events, telaprevir-based therapy can increase the proportion of achieving SVR in both previously treated and untreated chronic HCV-1 infected patients.
format	article
author	Yuan Kong Xiaoping Wang Yushu Shang Paul M Schroder Wenhua Liang Xiaoting Ling Zhiyong Guo Xiaoshun He
author_facet	Yuan Kong Xiaoping Wang Yushu Shang Paul M Schroder Wenhua Liang Xiaoting Ling Zhiyong Guo Xiaoshun He
author_sort	Yuan Kong
title	Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
title_short	Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
title_full	Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
title_fullStr	Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
title_full_unstemmed	Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.
title_sort	efficacy and tolerability of telaprevir for chronic hepatitis virus c genotype 1 infection: a meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/9bb02f5ccd264deb9697c71e82c55b96
work_keys_str_mv	AT yuankong efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis AT xiaopingwang efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis AT yushushang efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis AT paulmschroder efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis AT wenhualiang efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis AT xiaotingling efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis AT zhiyongguo efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis AT xiaoshunhe efficacyandtolerabilityoftelaprevirforchronichepatitisviruscgenotype1infectionametaanalysis
_version_	1718422303404982272

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.

Ejemplares similares